Table 1.
Demographic and clinical characteristics at randomization
| All (%)a | Ciprofloxacin | Trimethoprim-sulfamethoxyzole | Observation | ||
|---|---|---|---|---|---|
| n = 212 | n = 69 | n = 76 | n = 67 | ||
| Male | 133 (62.7%) | 46 | 44 | 43 | |
| White | 160 (77.7%) | 54 | 51 | 55 | |
| Infection in last 6 months | 28 (13.5%) | 13 | 7 | 8 | |
| Regimen | MP | 34 (16.5%) | 11 | 13 | 10 |
| VBMCP | 22 (10.7%) | 6 | 8 | 8 | |
| VAD | 63 (30.6%) | 24 | 17 | 22 | |
| Other | 87 (42.2%) | 28 | 36 | 23 | |
| ECOG performance status | Mean | 1.0 | 1.0 | 1.1 | 0.8 |
| Minimum | 0 | 0 | 0 | 0 | |
| Maximum | 4 | 3 | 4 | 4 | |
| Age | Mean | 63.8 | 63.7 | 62.6 | 65.0 |
| Minimum | 32.4 | 32.4 | 36.7 | 36.2 | |
| Maximum | 89.3 | 86.0 | 85.7 | 89.3 |
Abbreviation: ECOG, Eastern Cooperative Oncology Group; MP, melphalan and prednisone; VBMCP, vincristine, carmustine, melphalan, cyclophosphamide and prednisone; VAD, vincristine, adriamycin and dexamethasone.
a
Not statistically significant difference between the groups.